



Wednesday, February 22, 2023

13:00-14:30	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)				
14:30-16:00		PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL VIRTUAL SESSION (Pre-recorded) - TECH FAIR WINNERS SESSION (14:30 – 17:10) (not included in the main event CME/CPD credit)
16:15-17:45		PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL #DEDOC° SYMPOSIUM THE PATIENT PERSPECTIVE: WHAT WE WISH YOU KNEW - AND WHY	
18:00-19:00	OPENING CEREMONY <u>Tadej Battelino</u> - Opening remarks OPENING LECTURE <u>Chantal Mathieu</u> – The new face of diabetes				
19:00-20:00	NETWORKING RECEPTION (in the Exhibition Area)				

Thursday, February 23, 2023

08:30-10:00	PLENARY SESSION – CGM USE IN TYPE 2 DIABETES AND BEYOND <u>Rich Bergenstal</u> - Use of CGM with people with diabetes type 2 not treated with insulin <u>Lalantha Leelarathna</u> - Use of CGM with people with diabetes type 2 treated with basal insulin only <u>Melissa Putman</u> - Use of CGM in the cystic fibrosis population <u>Satish Garg</u> – The vision of the future of CGM in type 2 diabetes
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES
10:30-12:00	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES

13:00-14:30	PARALLEL SESSION RESOLVING HYPOGLYCEMIA	PARALLEL SESSION DECISION SUPPORT SYSTEMS	PARALLEL SESSION TECHNOLOGY USE IN PREGNANCY	PARALLEL SESSION EXERCISE IN DIABETES	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (1)
	<p><u>Simon Heller</u> - What reduction in hypoglycemia from interventions should be considered clinically meaningful</p> <p><u>Pratik Choudhary</u> - Difference between CGM detected and patient reported hypoglycemia</p> <p><u>Frans Pouwer</u> - The impact of hypoglycemia: What do studies using patient reported outcomes tell us</p> <p><u>Bastiaan de Galan</u> - Learnings from the Hypo-RESOLVE project</p>	<p><u>Revital Nimri</u> - Real-world data on the use of decision support systems</p> <p><u>Peter Jacobs</u> - Incorporating explainability and interpretability into AI-enabled decision support systems?</p> <p><u>Leah Wilson</u> - Artificial intelligence and decision support systems</p> <p><u>Korey Hood</u> - Patient reported outcomes in closed loop studies</p>	<p><u>Sarit Polsky</u> - Do we need pregnancy specific closed-loop algorithms?</p> <p><u>Lois Donovan</u> - Psychosocial impact of using closed-loop systems during pregnancy</p> <p><u>Helen Murphy</u> - Automated insulin delivery in type 1 diabetes pregnancy - are we nearly there yet?</p> <p><u>Yariv Yogev</u> - Should we suggest weight loss during pregnancy for obese women with diabetes?</p>	<p><u>Kirsten Nørgaard</u> - Exercise with AID</p> <p><u>Dessi Zaharieva</u> - Is technology useful for breaking down barriers to exercise in diabetes?</p> <p><u>Lia Bally</u> - Physical activity with long and ultra-long-acting basal insulins</p> <p><u>Ali Cinar</u> - Automated detection of meals and exercise events in people with diabetes</p>		
14:30-15:00	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES					
15:00-16:30	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)					

16:40-18:10	PARALLEL SESSION EMERGING TREATMENT OPTIONS FOR OBESITY AND TYPE 2 DIABETES	PARALLEL SESSION JDRF SESSION - CONTINUOUS KETONE MONITORING FOR TYPE 1 DIABETES	PARALLEL SESSION AID EXPERIENCE IN THE REAL- WORLD	PARALLEL SESSION CLOSED-LOOP IN ACTION	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (2)
	<p><u>Mojca Jensterle Sever</u> - GLP-1 Analogs for the treatment of Obesity</p> <p><u>Juan Frias</u> - Unimolecular multiagonists (dual and triple) for the management of obesity and cardiorenal risk – An update</p> <p><u>Julio Rosenstock</u> - Challenging treatment guidelines: Reversing type 2 DM from Day One</p> <p><u>Walter Pories</u> - Bariatric surgery: An update</p>	<p><u>David O’Neal</u> - Clinical need for continuous ketone monitoring integrated into CGM devices (i.e. CGM-CKM)</p> <p><u>Rodica Busui</u>: SGLT inhibitors in T1D: DKA risk and DKA risk mitigation strategies, especially CGM-CKM, to enable therapy use for heart and kidney health</p> <p><u>Idan Tamir</u>: Pre- clinical development of CGM-CKM</p> <p><u>Shridhara Alva</u>: Feasibility and performance of a continuous ketone monitoring sensor</p>	<p><u>Eric Renard</u> – French Children</p> <p><u>Regis Radermecker</u> – In Belgium</p> <p><u>Emma Wilmot</u> – In the United Kingdom</p> <p><u>Helen Murphy</u> – In pregnancy</p>	<p><u>Roman Hovorka</u> - Closing the loop – from cradle to mature age</p> <p><u>Ahmad Haidar</u> - Closed- loop with adjunct therapies</p> <p><u>Stuart Weinzimer</u> - Postprandial glucose control in advanced hybrid closed-loop systems</p> <p><u>Peter Jacobs</u> - Leveraging behavioral and physiologic patterns collected from wearable sensors and a smart-home to augment next-generation closed- loop algorithms</p>			

Friday, February 24, 2023

08:00-08:50	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
09:00-10:00	PARALLEL SESSION CARDIOVASCULAR DIABETES	PARALLEL SESSION DERMATOLOGY IN DIABETES	PARALLEL SESSION WEEKLY INSULINS	PARALLEL SESSION NON-INVASIVE GLUCOSE MONITORING: REALITY VS. HYPE	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (3)
	<p><u>Viral Shah</u> – Causes of cardiovascular disease and insulin resistance in type 1 diabetes</p> <p><u>Antonio Ceriello</u> - Cardiovascular outcome trials (CVOT): Which role for risk factors control?</p> <p><u>Oliver Schnell</u> – Cardiovascular outcome trials (CVOTs) in diabetes - A success story that has changed the landscape of diabetes therapy</p>	<p><u>Irl Hirsch</u> - Skin and the insulin pump: New findings</p> <p><u>Laurel Messer</u> - Skin integrity, tips, tricks, and hacks for sustained device use</p> <p><u>Sumita Pennathur</u> - Long term solutions for improving infusion site challenges for insulin pumps</p>	<p><u>Julio Rosentock</u> - Update on weekly Icodec Insulin: Lessons from the ONWARD Clinical Development Program</p> <p><u>Juan Frias</u> - Once Weekly Basal Insulin Fc (BIF): An update on the type 2 diabetes clinical development program</p> <p><u>Steven Edelman</u> - Once weekly insulins in Type 1 diabetes: Safety, efficacy and does it address an unmet need?</p>	<p><u>Bruno Thuillier</u> - Non-invasive glucose monitoring: Breath, a realistic option?</p> <p><u>Christophe de Block</u> - Continuous ketone monitoring</p> <p><u>Anders Weber</u> - Raman Ni-BGM from conception to real world clinical device; are we there yet?</p>			
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
10:30-12:00	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						

13:00-14:30

ATTD YEARBOOK SESSION

Satish K. Garg - Virtual clinics for diabetes care

Klemen Dovc - Continuous and intermittent glucose monitoring

Rayhan Lal - Insulin delivery hardware: Pumps and pen

Thomas Pieber - New insulins, biosimilars and insulin therapy

Revital Nimri - Closed-loop and artificial intelligence-based decision support systems

Marc Clements - Using digital health technology to prevent and treat diabetes

Jennifer Yamamoto - Technology and pregnancy

David Maahs - Diabetes technology and therapy in the pediatric age group

Dessi Zaharieva - Advances in exercise and nutrition as therapy in diabetes

Gregg Simonson - Primary care and diabetes technologies and treatments

Stuart Weinzimer - Real-world diabetes technology: Overcoming barriers & disparities

Alon Liberman - Diabetes technology and the human factor

Desmond Schatz - Immune interventions and restorative therapies in type 1 diabetes

Irl Hirsch - New medications for the treatment of diabetes

Viral Shah - Obesity and diabetes

14:30-15:00

COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES

15:00-16:30	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
16:40-18:10	PARALLEL SESSION SOME MORE HIGHLIGHTS IN DIABETES <u>Guido Freckmann</u> - Why do CGM performance assessments need more standardization? <u>Gregory Forlenza</u> - Can Hybrid Closed Loop and/or Verapamil Prolong Islet Survival in new onset type 1 diabetes? Results from the JDRF CLVer Trial <u>Francesco Rubino</u> - Surgical treatment of obesity and type 2 diabetes: Outcomes, mechanisms and future perspectives <u>Nebojsa Lalic</u> - The use of SAP In pregnancy: Comparison of the initiation of the treatment before and after conception	PARALLEL SESSION TIMES IN RANGES <u>Thomas Danne</u> - What is the clinical relevance of TIR/TAR 70-140 mg/dl for T1D and T2D? <u>Peter Adolfsson</u> - Time in tight range in type 1 diabetes <u>Tadej Battelino</u> - Time in tight range in type 2 diabetes <u>David Rodbard</u> - TIR and other Times in Ranges are better than HbA1c as metrics for quality of glycemic control	PARALLEL SESSION ADVANCES IN FULLY AUTOMATED CLOSED-LOOP <u>Patricio Colmegna</u> - Automated control meets behavior: Human-machine co-adaptation of the artificial pancreas <u>Michael Riddell</u> - Closing the loop on exercise <u>Klemen Dovc</u> - Ultra-rapid insulin and anticipatory algorithms <u>Boris Kovatchev</u> - Fully-automated closed-loop control: Challenges and potential solutions	PARALLEL SESSION FEAR OF HYPERGLYCEMIA <u>Alon Liberman</u> - Fear of hyperglycemia in parents of children with type 1 diabetes <u>Bruce Bode</u> - Management of hyperglycemia in the hospital using closed-loop systems <u>Irl Hirsch</u> - Update on glycemic targets in the ICU <u>Nataša Bratina</u> - Avoiding hyperglycemia from diabetes onset	PARALLEL SESSION TECHNOLOGY FOR THE HEALTHY AGING OF OLDER PEOPLE WITH DIABETES <u>Medha Munshi</u> - Why healthy aging with diabetes is a challenge? <u>Tali Cukierman-Yaffe</u> - Adverse outcomes of hyperglycemia & hypoglycemia in older people with diabetes- how should the recommended target % TIR be determined? <u>Richard Pratley</u> - The use of CGM in older people with diabetes <u>David O'Neal</u> - The use of hybrid closed systems in older people with diabetes	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (4)
19:00-21:30	OFF-SITE ATTD PARTNER EVENT (not included in the main event CME/CPD credit)							

Saturday, February 25, 2023

08:00-09:10	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)					
09:30-11:00	PARALLEL SESSION REMOTE TREATMENT OF DIABETES	PARALLEL SESSION NUTRITION AND FOOD TECHNOLOGIES	PARALLEL SESSION DESPAIR AND SELF-HARM & DIABETES TECHNOLOGY	PARALLEL SESSION PRACTICAL ISSUES IN DAILY LIFE OF PEOPLE WITH DIABETES	Oral (5)	Oral (6)
	<p><u>Mark Clements</u> – Population health management in the digital diabetes era</p> <p><u>Paul Wadwa</u> - Challenges in implementing telehealth for diabetes care</p> <p><u>David Maahs</u> - ECHO study - Delivering tele-education on diabetes to primary care physicians in underserved areas</p> <p><u>Robert Ratner</u> - Outcomes of continuous remote care in pre-diabetes and type 2 diabetes</p>	<p><u>Andrea Scaramuzza</u> – Strategies for mitigating glycemic excursions following unannounced meals with existing technologies</p> <p><u>Maya Laron-Hirsh</u> - Complex meal handling with advanced hybrid closed-Loop system</p> <p><u>Maria Vasiloglou</u> - What healthcare professionals and end-users need in image-based nutrition apps</p> <p><u>Michal Gillon-Keren</u> Mobile application for carbohydrate counting - personalized nutrition</p>	<p><u>Lori Laffel</u> - Addressing opportunities to Improve glycemic control and limit diabetes distress</p> <p><u>Katharine Barnard-Kelly</u> - Understanding clinical relevance on a PRO</p> <p><u>Marc Breton</u> - Machine learning and big data to identify individuals at risk</p> <p><u>Marissa Town</u> - What matters to the person with diabetes when choosing diabetes technologies</p>	<p><u>John Pemberton</u> - The issues with using CE Mark as a valid proxy for continuous glucose monitoring systems accuracy for people with type 1 diabetes</p> <p><u>Emma Wilmot</u> - Helping adults choose a safe and effective CGM in light of new national guidance</p> <p><u>Ramzi Ajjan</u> - Is it easy to use time in range (TIR) for daily management of diabetes?</p> <p><u>Mark Evans</u> - The regulations around driving and diabetes</p>		

11:00-11:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
11:30-13:00	PARALLEL SESSION DIABETES INDIA	PARALLEL SESSION JDRF SESSION - MONITORING PRE- SYMPTOMATIC TYPE 1 DIABETES: WHICH TECHNOLOGY FOLLOWS AUTOANTIBODY DETECTION?	PARALLEL SESSION DATA SCIENCE IN DIABETES	PARALLEL SESSION GLUCOSE MANAGEMENT IN THE PEDIATRIC AND ADULT FEMALE POPULATION	Oral (7)	PARALLEL SESSION FIGHTING DISPARITIES	Oral (8)
	<p><u>Banshi Saboo</u> - Introduction</p> <p><u>Amit Gupta</u> - Personalized medicine to precision medicine: India is changing</p> <p><u>Rakesh Parikh</u> - Diabetes technology - the make in India story</p> <p><u>Manoj Chawla</u> - Diabetes management in India - challenges & tech solutions</p> <p><u>Mithun Bhartia</u> - Opportunities and Threats analysis (SWOT) of blood sugar monitoring in India</p> <p><u>Jothydev Kesavadev</u> - Do it yourself artificial pancreas: The affordable Indian experiences</p>	<p><u>Sanjoy Dutta</u> - Introduction</p> <p><u>Michael Haller</u> - The strengths and limitations of monitoring via OGTT</p> <p><u>Chantal Mathieu</u> - The evidence for alternative monitoring technologies</p> <p><u>Kimber Simmons</u> - What's feasible in the clinical care setting?</p>	<p><u>Amy Criego</u> - Improved data collection: Moving CGM reports from the patient directly to the EMR</p> <p><u>David Scheinker</u> - Algorithm-enabled RPM for T1D; lessons from the 4T study for a continuously learning health system</p> <p><u>Gregory Forlenza</u> - Data ownership and use of data aggregators in clinical care</p> <p><u>Mark Clements</u> - Deep learning to predict diabetes outcome</p>	<p><u>Eda Cengiz</u> - Technological gadgets: What is available to girls and women with diabetes</p> <p><u>Darja Šmigoc Schweiger</u> - Gender differences in cardiovascular risk markers in young population with type 1 diabetes</p> <p><u>Dessi Zaharieva</u> - Sex differences in the management of exercise in the pediatric and adult population</p> <p><u>Chiara Fabris</u> - Insulin dosing in women with T1D: Is there a need for tailored solutions?</p> <p><u>Katharine Barnard – Kelly</u> - Psycho-behavioral barriers to optimal glucose management in women with T1D across the ages</p>		<p><u>Lori Laffel</u> - Understanding and overcoming health disparities in use of diabetes technologies</p> <p><u>Partha Kar & Jazz Sethi</u> - Fighting disparities: Different worlds</p> <p><u>David Maahs</u> - Bridging Disparities in Type 1 Care in the US</p> <p><u>Viswanathan Mohan</u> - Advocacy and adoption of technology and disparities in India</p>	

13:00-13:45	LUNCH, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
13:45-14:45	PARALLEL SESSION DIABETES TECHNOLOGY AND WASTE: HOW TO TURN GREENER?	PARALLEL SESSION EMERGING TECHNOLOGIES FOR DIABETES	PARALLEL SESSION ISPAD SESSION	PARALLEL SESSION MIND THE FOOT!	Oral (9)	Oral (10)	Oral (11)
	<p>David Kerr - The greening of diabetes care in America</p> <p>Lutz Heinemann - Diabetes technology and waste: How to turn greener? - The EU point of view</p> <p>Matthias Axel Schweitzer - Diabetes technology and waste: How to turn greener? - The manufacturers' point of view</p>	<p>Simon Friedman – Replacing pumps with light controlled insulin delivery</p> <p>Idan Tamir - Continuous Lactate Monitoring (CLM) – A new paradigm for monitoring high-risk diabetic patients</p> <p>Claudio Cobelli & Alfonso Galderisi - Beyond the glucose-centric diabetes management: The path to multiple sensing</p>	<p>Roque Cardona-Hernandez - Global Registry data: Diabetes Technology impact</p> <p>TBD - Psychological impact of technology: What is most relevant?</p> <p>Jamie Wood - Diabetes technology access in low and middle low-income countries: Now or later</p>	<p>Andrew Boulton - New evidence-base therapies for complex diabetic foot wounds</p> <p>Julia Mader - Monitoring of diabetic foot disease</p> <p>Prash Vas - Developing a functional multidisciplinary foot service of the future: Integrating team working and technology</p>			
14:55-15:55	PLENARY SESSION SCREENING AND PREVENTION OF TYPE 1 DIABETES						
	<p>Rachel Besser – Screening of general population – Current status around the world</p> <p>Laura Jacobsen – Emerging biomarkers of responses to immunotherapies</p> <p>Jay Skyler – Stem cell approaches to type 1 diabetes</p>						
15:55-16:25	CLOSING REMARKS						
	100 YRS INSULIN PRIZE						
16:25	FAREWELL REFRESHMENTS						